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ABSTRACT 
THE ROLE OF MATRIX METALLOPROTEINASES INDUCED ANGIOGENESIS 
DURING TRANSITION FROM COMPENSATORY CARDIAC HYPERTROPHY 
TO CARDIAC FAILURE: THERAPEUTIC EFFECTS OF HYDROGEN SULFIDE. 
Dr.Srikanth Givvimani M.D 
July 26th 2010 
Background: Although matrix metalloproteinase (MMPs) and tissue inhibitor of 
metalloproteinase (TIMPs) playa vital role in tumor angiogenesis and TIMP-3 
causes apoptosis, their role in cardiac angiogenesis is unknown. Interestingly, a 
disruption of coordinated cardiac hypertrophy and angiogenesis contributes to 
the transition to heart failure, however, the proteolytic and anti-angiogenic 
mechanisms of transition from compensatory hypertrophy to decompensatory 
heart failure are unclear. Previous studies have shown the cardio protective role 
of hydrogen sulfide (H2S) in myocardial ischemia, infarction and heart failure, but 
its role during transition from compensatory cardiac hypertrophy to heart failure is 
yet to be unveiled. We hypothesize that in pathological pressure overload of the 
heart, cardiac matrix remodeling is induced by an increase in angiogenic growth 
factors during the compensatory hypertrophy phase and an increase in anti-
angiogenic factors during the decompensatory heart failure phase. H2S mitigates 
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the transition from compensatory hypertrophy to decompensatory heart failure by 
increasing angiogenesis and decreasing fibrosis. 
Methods: In the first set of experiments, we have created ascending aortic 
banding (AB) in the mice to mimic pressure overload on the heart and studied the 
ventricular remodeling events associated with chronic pressure overload. Male 
wild type mice were used and all animal procedures were performed in 
accordance with National Institute of Health guidelines for animal research and 
were reviewed and approved by the Institute Animal Care and use Committee of 
University of Louisville. Sham animals underwent similar procedures except for 
aortic banding. Animals were studied at 3 weeks (compensatory phase) and 8 
weeks period (decompensatory phase) and compared with sham groups. 
In the second set of experiment, similar protocol was followed, and 
animals were treated with hydrogen sulfide (H2S) for 6 weeks by giving sodium 
hydrosulfide (NaHS) in drinking water and compared with untreated groups. 
Molecular and functional data were assessed by echocardiography, pressure-
volume (P-V) study, immunohistochemistry, histology, western blot, and x-ray 
angiography. 
Results: We found that in the first set of experiments, expression of MMP-2 
increased along with angiogenic growth factor, vascular endothelial growth factor 
(VEGF) during compensatory phase (AB 3 weeks group). Expression of MMP-9, 
TIMP-3 and anti-angiogenic factors, angiostatin, and endostatin increased during 
decompensatory phase (AB 8 weeks group). There was increased deposition of 
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fibrosis during the decompensatory phase. Sy treating with H2S, we noticed that 
there was increased expression of VEGF and MMP-2 in AS 8 weeks group than 
in untreated AS 8 weeks group. Interestingly, the expression of MMP-9, TIMP-3 
and anti-angiogenic factors angiostatin and endostatin decreased in H2S treated 
AS 8 weeks group than in the untreated group. There was significant reduction of 
fibrosis in treated AS 8 weeks group. Left ventricular function also improved in 
H2S treated AS 8 weeks group. 
Conclusion: we conclude that under chronic pressure overload, expression of 
MMP-2 is induced which in turn increases the release of angiogenic growth 
factors in compensatory cardiac hypertrophy. The expression of MMP-9 and 
TIMP-3 is also increased leading to a release of anti-angiogenic factors in 
decompensatory heart failure. Hydrogen sulfide mitigates this transition to 
decompensatory heart failure not only by inducing MMP-2NEGF but also 
inhibiting MMP-9/TIMP-3 and anti-angiogenic factors. 
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CHAPTER I 
INTRODUCTION 
Worldwide, cardiovascular disease (CVD) is the leading cause of mortality for 
both men and women (Figures 1 and 2) (1). It includes hypertension, ischemia, 
infarction, heart failure and stroke. Hypertension is one of the major risk factors 
of heart failure. Nevertheless, it is unclear, why every hypertensive does not 
develop heart failure. To develop treatment of CVD, it is important to determine 
the mechanism(s) of heart failure. In 1941 Roberts et al. report that there is a 
decreased ratio of capillary density to number of myofibers in hypertrophied 
hearts, stressing the importance of angiogenesis in the pathogenesis of heart 
failure. Since then wide range of research is ongoing to unravel the pathogenic 
mechanism of heart failure. 
Chronic heart failure (CHF) could be due to pressure overload and/or 
volume overload. Systemic hypertension is the main risk factor of pressure 
overload heart failure. Previous studies have shown that during chronic stress, 
the heart undergoes remodeling resulting in compensatory hypertrophy initially, 
and progressing to decompensatory heart failure in later stage. Remodeling by 
its very nature implies synthesis and degradation of extracellular matrix (ECM). 
The matrix metalloproteinase (MMP) and their natural tissue inhibitors (TIMPS), 
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play a major role in ECM remodeling and the pathogenesis of heart failure. 
Proper angiogenesis/vasculogenesis is important to supply nutrients to the 
remodeling tissue. It has been shown that disruption in the angiogenic process 
leads to decompensatory heart failure, however, the exact mechanism of 
transition from compensatory hypertrophy to decompensatory heart failure has 
not been elucidated. Although angiogenic and anti-angiogenic factors have been 
extensively studied, and a critical role of MMPfTlMP axis in cancer has been 
demonstrated, their role in cardiac pathology has not been studied. In contrast to 
cancer, angiogenesis or inhibition of anti-angiogenic factors may playa beneficial 
role in ischemic cardiovascular diseases including heart failure, and therefore 
pro-angiogenic therapy is a promising strategy for the treatment of cardiovascular 
disease. 
Hydrogen sulfide has recently been found to be an endogenous gaseous 
transmitter similar to nitric oxide (NO) and carbon monoxide (CO). Several 
mechanisms have been proposed to show the cardio protective vasodilatory and 
pro-angiogenic mechanisms of hydrogen sulfide. Nevertheless, it is not known 
whether hydrogen sulfide can have a therapeutic role in hypertension-induced 
heart failure. In the present study, we examined the mechanisms involved in the 
transition from compensatory to decompensatory heart failure, and the 
therapeutic effects of hydrogen sulfide during this transition. 
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Figure 1: Deaths due to cardio vascular disease in United States from 1900-
2006 (AHA statistical update). The plateau during 1980 could be due to 
awareness of healthy nutrition and advances in the medical management. 
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Figure 2: Prevalence of cardio vascular disease in adults ~ 20 years of age by 
age and sex (NHANES: 2005-2006). Source NCHS (National center for health 
statistics) and NHLBI (National Heart, Lung and Blood Institute). 
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CHAPTER II 
BACKGROUND 
a) Structure and function of the heart 
The heart is a four chambered pumping organ (upper right and left atria 
and lower right and left ventricles) in which the left side of the heart receives 
oxygenated blood through pulmonary veins from the lungs and pumps it to the 
rest of the body through the aorta. The right side of the heart receives 
deoxygenated through the superior and inferior venacava, and pumps it to the 
lungs via the pulmonary artery. The main function of the heart is to receive and 
pump blood in a rhythmic manner (2). During contraction, the heart pumps blood 
against the aortic pressure (afterload) which reflects vascular resistance. The 
work load on the heart can be increased either by an increase in vascular 
resistance (pressure overload) or by an increase in venous return (volume 
overload). As the work load increases, the heart muscle has an intrinsic 
compensatory mechanism to overcome the load and remodel accordingly. 
Anatomically the heart can be differentiated into three layers: an inner 
endocardial layer, middle myocardial layer and an outer epicardial layer. The 
heart is surrounded by a pericardial sac and in the pericardial space there is 
pericardial fluid that provides protection to the heart from external force or 
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friction. The cellular structure of the heart consists of myocytes, fibroblasts, 
smooth muscle cells, endothelial cells and extracellular matrix. Ventricular 
myocytes contribute to 70 - 80% of the total cardiac mass (3) and the contractile 
proteins of the heart lie within the myocytes. A group of myocytes held together 
by collagenous connective tissue (a major component of extracellular matrix), is 
called a myofiber. Approximately 50% of each ventricular cell is comprised of 
myofibers and 25 - 33% consists of mitochondria (4). Vascular supply to the 
heart is mainly by the right and left coronary arteries which arise from the aorta 
just above the aortic valves. The left coronary artery divides into the left anterior 
descending and the left circumflex arteries which supply most of the anterior 
region, septum and posterior regions. The right coronary artery supplies the 
lateral region of the right ventricle, right atrium and part of the posterior wall of 
right ventricle (Figure 3). The specialized conduction system of the heart 
originates in the sino atrial node (intrinsic pacemaker) in the high right atrium. 
Impulses from the sino atrial node traverses through the atria to the atrio 
ventricular node and then through the common bundle of His, which divides in 
the ventricular septum as right and left bundle branches and terminates in 
Purkinje fibers (Figure 4). 
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Figure 3: Blood supply of the heart. Left coronary artery divides into left 
anterior descending and left circumflex arteries which supply most of the anterior 
region , septum and posterior regions. Right coronary artery supplies lateral 
region of the right ventricle, right atrium and some part of the posterior wall of 
right ventricle. 
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node ---7 His bundle----7Right and left bundle branches---7 Purkinje fibers. 
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b) Pathological conditions of the heart 
Hypertension 
High blood pressure / hypertension is a major risk factor of cardiovascular 
diseases. According to the guidelines of the American heart association (AHA), 
hypertension is defined as a systolic blood pressure (SBP) of ~ 140 mm Hg or a 
diastolic blood pressure (DBP) of ~ 90 mm Hg. One in three adults in United 
States is hypertensive (1, 5) and it is estimated that direct and indirect health 
care cost associated with treatment of hypertension is $73.4 billion per year (1). 
Increase in blood pressure during hypertension leads to adverse events in the 
brain, heart, and kidneys through two related mechanisms. The first is the effect 
of increased pressure on the structure and function of the heart and arteries, and 
the second is the acceleration of atherogenesis. The former is directly related to 
the blood pressure, whereas the latter requires an interaction with other CVD risk 
factors, most importantly cholesterol (6). Hypertension increases pressure 
overload (afterload) on the heart and influences cardiac remodeling. At the onset 
of hypertension, the heart rate increases to compensate for the increase in 
overload. Over time myocytes increase in size to further compensate for the 
increased afterload by increasing the force of contraction to maintain stroke 
volume. As the overload is sustained long-term, myocardial remodeling 
progresses to an increase in wall thickness and chamber size that leads to 
contractile dysfunction and heart failure (7-8). The structural abnormalities in the 
hypertensive heart are not only limited to myocyte hypertrophy but also include 
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medial hypertrophy of the intramyocardial coronary arteries as well as collagen 
deposition leading to cardiac interstitial fibrosis (4). 
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Cardiac hypertrophy 
Hypertrophy of the cardiac myocyte can be either physiological, during 
growth and exercise or it can be pathological, due to a persistent increase in 
mechanical overload (9). Pathological hypertrophy has been associated with 
pressure overload, volume overload, and ischemic cardiomyopathy (4). Unlike 
physiological cardiac hypertrophy, pathological hypertrophy results in the loss of 
myocytes and their fibrotic replacement leading to cardiac dysfunction and 
sudden cardiac death (10-11). Pressure overload produces a disproportionate 
increase in systolic wall stress, and results in concentric ventricular hypertrophy. 
At the cellular level, cardiomyocyte cross-sectional area is increased, 
predominantly because of the parallel addition of new sarcomeres. Volume 
overload can induce either systolic or diastolic wall stress and result in eccentric 
ventricular hypertrophy. Eccentric hypertrophy results in an overall increase in 
myocyte length without a substantial increase in myocyte cross-sectional area 
and is caused by the addition of new sarcomeres in series (12-13). 
Sustained pressure overload results in excessive collagen deposition, an 
increase in myocyte size, and a decrease in capillary density leading to heart 
failure (Figure 6) (14). In 1941 Roberts et al. demonstrated a decrease in 
capillary to myocyte diameter ratio in hypertrophied human hearts compared with 
normal adult hearts (Fig 5) (15). The coronary blood flow is normal during 
diastole in the hypertrophied heart but the vasodilatory reserve becomes 
impaired, when the myocyte mass surpasses the blood supply. This impairment 
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in the coronary reserve leads to subendocardial ischemia and in combination 
with cardiac fibrosis impairs diastolic relaxation leading to diastolic heart failure. 
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normal, hypertrophied and atrophied hearts (reproduced from 1941 article by 
Dr. Roberts et aI. , Am Heart journal). The data show that as the fiber diameter 
increases in hypertrophied heart there is a decrease in capillary density. 
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Normal CHF 
Figure 6: Relationship of capillary endothelial cell density to the cardiac myocyte 
hypertrophy (14) . There is lower capillary density and excessive deposition of 
ECM in congestive heart failure heart (CHF) than in normal heart. Arrows point 
to the capillaries (white) , hypertrophied myocyte (yellow) , and fibrosis (black) . 
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Heart failure 
According to the American Heart Association (AHA), an estimated 5.7 
million of Americans are suffering with heart failure and 670, 000 new cases are 
diagnosed each year. The estimated direct and indirect cost of treating heart 
failure in the United States in 2009 was $37.2 billion per year (1). 
Heart failure is defined as a pathophysiological state in which an 
abnormality of cardiac function decreases the ability of the heart to pump blood 
at a rate commensurate with the requirements of the metabolizing tissues (4). 
Heart failure can also be better defined as a complex clinical syndrome that can 
result from any structural or functional cardiac disorder that impairs the ability of 
the ventricle to fill with or eject blood (16). 
Heart failure can be due to: a) loss of myocytes (e.g., myocardial 
infarction) or disorientation of cells (e.g., hypertrophic), b) an increase in afterload 
(e.g., hypertension) c) valvular abnormalities d) arrhythmias, e) pericardial 
abnormalities, and f) congenital deformities of the heart (6). A clinical study 
performed in 1993, reported changes in wall stress, wall thickness and 
ventricular volume (Figure 7) (17), associated with the progression of 
compensatory hypertrophy to decompensatory heart failure. 
Cardiac structural adaptations and maladaptations during remodeling 
Under chronic pressure overload, compensatory hypertrophy occurs with 
addition of sarcomeres in parallel, leading to thickening of myocytes without a 
change in length. Sustained overload leads to the addition of new sarcomeres in 
15 
series, resulting in the dilatation of the ventricles. Also excessive stretch of 
myocytes can lead to myocyte death, resulting in the deposition of collagen 
(fibrosis) in heart failure (6). 
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.. Figure 7: Morphological and functional changes during progression of 
heart failure: clinical study by Pouler HG et aI. , (1993) showing the 
morphological and functional changes associated with progression of heart 
failure. During the compensatory period, the wall thickness gradually increases 
while the wall stress and ejection fraction remain constant, whereas during 
decompensatory stage the wall thickness and ejection fraction decrease while 
the wall stress increases. 
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c) Extracellular matrix 
Cardiac extracellular matrix (ECM) is the collagenous structural foundation 
which entangles cardiac myocytes, vascular smooth muscle cells and endothelial 
cells to form a network in the heart. In the myocardium, cellular structures are 
connected to ECM through integrins which provide a physical connection 
between the cell surface and surrounding proteins in the matrix (Figure 8) (18-
19). The main components of myocardial ECM are type I and type III collagen, 
which provide the structural integrity of the heart. Abnormal turnover of collagen 
results in interstitial and perivascular fibrosis, leading to stiffening of the ventricle 
(20-21 ). 
It has been identified that not only the poor contractile nature of myocytes 
but also the disturbance in the ECM contributes to the pathogenesis of cardiac 
failure (22-23). Chronic heart failure is characterized by an imbalance in ECM 
turnover leading to an accumulation of collagen in the myocardium, loss of 
myocytes, and disruption of collagen fibrils (23-25). Remodeling, by its very 
nature, implies synthesis and degradation of ECM, leading to alterations in the 
ECM composition and concentration, but it is the aberrant remodeling in the 
myocardial ECM that results in heart failure. The integrity of the ECM is regulated 
by matrix metalloproteinases (MMPs) and their tissue inhibitors called tissue 
inhibitors of matrix metalloproteinases (TIMPs). 
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A) Normal B) Compensatory Hypertrophy 
(Pressure overload) 
C) Decompensatory 
heart failure 
Figure 8: Representation of extracellular matrix remodeling in the pathogenesis 
of heart failure. A) Normal myocytes with intact matrix 8) Hypertrophied 
myocytes with disrupted matrix and C) Disordered myocytes with excessive 
interstitial matrix. 
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d) Matrix metalloproteinases 
Matrix metalloproteinases (MMPs) were first discovered by Jerome Gross 
and Charles Lapiere in 1962 who observed the enzymatic activity in tadpole tail 
metamorphosis (26). MMPs are calcium and zinc dependent extracellular 
endopeptidases which are synthesized as inactive pro enzymes that need to be 
activated either by auto proteolysis or by another MMP or serine proteases (23). 
To date nearly 30 MMPs have been identified and are mainly classified as 
collagenases, gelatinases, stromelysins, and membrane type (Figure 9) (23, 27-
28). Collectively MMPs can process and degrade all components of extracellular 
matrix (29-30). 
Tyagi and colleagues have demonstrated that myocardial latent MMPs 
can be activated by oxidative stress during heart failure (31) . MMPs associated 
with myocardial remodeling are, a) Collagenases: MMP-1 and MMP-13, b) 
stromelysins: MMP-3, c) gelatinases: MMP-2 and MMP-9 and d) membrane type 
matrix metalloproteinase: MMP-14 (Table 1) (23, 32). Rodents lack MMP-1, 
however, MMP-13 replaces its function and degrades collagen types I, II, and III 
(33). MMP-14 cleaves fibronectin, gelatin, and laminin-1 (34). MMP-2 and -9, 
degrade collagen types I, IV, V. MMP-2 also cleaves collagen type III fragments 
(35-36). MMPs act not only on ECM proteins but also on various cytokines and 
growth factors. MMPs also influence cell proliferation, migration, differentiation 
during embryogenesis, angiogenesis, and apoptosis. They are also involved in 
host defense as well as tissue remodeling (37-40). MMPs play a role in 
20 
regulation of angiogenesis by altering the balance between angiogenic and anti-
angiogenic factors (41-43) . 
. 
Brooks and colleagues report that an angiogenic stimulus induces 
vascular remodeling and defines the role of MMP-2 and integrin (avr33) (44-45). 
During hypertrophic remodeling and angiogenesis, MMP-2 is constitutively 
expressed (41, 46). Alternatively, MMP-9 is expressed in heart failure and 
induces the expression of anti-angiogenic factors, endostatin and angiostatin (41, 
47-48). 
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Figure 9: A Basic domain structure of Matrix metalloproteinase is shown with the 
three most important domains: single peptide domain, pro peptide domain, and 
gelatin binding domain. Hemopexin domain plays an important role in substrate 
binding and interactions with TIMPs (49). B: Basic structural differences between 
different MMP types. 
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Table 1: Major classification of matrix metalloproteinases (MMPs) 
MMPs Cellular source Role in cardiac pathology 
Collagenases Fibroblasts, VSMCs, endothelial Left ventricular systolic 
MMP-1,-13 cells dysfunction 
Gelatinases 
MMP-2 VSMCs, fibroblasts, Pro angiogenic, improves 
macrophages cardiomyocytes, cardiac function 
MMP-9 VSMCs, neutrophils, fibroblasts, Anti-angiogenic, promotes 
cardiomyocytes, macrophages collagen deposition and 
fibrosis, cardiac dysfunction 
Stromelysins 
MMP-3,-7 VSMCs,fibroblasts,cardiomyocyt MMP-7 increases connexin 
es and macrophages processing and promotes 
arrhythmia 
Membrane 
type MMPs 
MT1- MMP VSMCs, fibroblasts and Adverse left ventricular 
cardiomyocytes remodeling and dysfunction 
VSMCs-vascular smooth muscle cells. 
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e) Tissue inhibitor of matrix metalloproteinases 
TIMPs are natural endogenous inhibitors of MMPs found in most tissues 
and body fluids that play an important role in extracellular matrix remodeling. 
TIMPs are 21-34 kDa proteins possessing 12 conserved cysteine residues. 
Cysteine residues form six disulfide bonds that fold the protein into two domains 
(Figure 10). TIMPs inhibit proteolytic activity of MMPs by forming non covalent 
1 : 1 stoechiometric complexes that are resistant to heat and proteolytic 
degradation (50). In humans, four TIMPs have been described namely, TIMP-1, -
2,-3, and -4. TIMP-1 ,-2, and -4 are present in soluble forms where as TIMP-3 is 
tightly bound to the matrix. TIMPs have differential action on matrix 
metalloproteinases (MMPs) and pro MMPs (51). 
TIMPs not only inhibit MMPs but also have the ability to form complexes 
with proMMPs and regulate the MMP activation process (52-56). TIMPs have a 
wide variety of actions such as promotion of cell growth, anti-apoptotic activity, 
steroidegenic activity, anti-angiogenic activity and embryogenic activity. The anti-
angiogenic activity of TIMPs was first demonstrated in chick embryo yolk sac (51, 
57). TIMP-3 exhibits strong anti-angiogenic activity that can be seen in all stages 
of angiogenesis (58). 
TIMPs in cardiac remodeling 
TIMPs have cellular actions that are independent of MMP inhibition. 
Studies report that the inhibitory actions of TIMP-1 to -3 on endothelial cell 
migration and/or angiogenesis in response to VEGF stimulation, is independent 
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of MMP inhibition (59). TIMPs induce proliferation of cardiac fibroblasts, which 
play an important role in cardiac remodeling. TIMP-3 shows differential action on 
cardiac fibroblasts depending on the time and localization of its expression after 
tissue injury. Table 2 summarizes the role of TIMPs during cardiac remodeling 
(60). 
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binding domain 
MMP binding 
pocket 
Figure 10: Tertiary structure of Tissue inhibitor of Matrix metalloproteinase 
(TIMP). Cysteines are linked to form six disulfide bridges 
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Table 2: Classification of tissue inhibitor of matrix metalloproteinases (TIMPs) 
TIMPs Cellular source Role in cardiac pathology 
TIMP-1 VSMC, EC, cardiomyocytes Induces fibrosis, inhibits all 
fibroblasts and macrophages MMPs except MMP-2 and MT1-
MMP 
TIMP-2 VSMC, EC, cardiomyocytes Induces cell proliferation, 
fibroblasts and macrophages inhibits all MMPs except MMP-
9, activates pro MMP-2 
TIMP-3 Cardiomyocytes, VSMC, Induced apoptosis, anti-
fibroblasts angiogenic. Inhibits MMP-1 ,-2, 
-13 
TIMP-4 VSMC,fibroblasts, Cardiac specific and induce 
cardiomyocytes apoptosis in transformed cells. 
Inhibits MMP-1 ,-3,-9. 
VSMC-vascular smooth muscle cell; EC-endothelial cell; MT1-MMP- membrane 
type matrix metalloproteinase. 
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f) Angiogenesis 
The sprouting of new capillaries from the existing blood vessels defines 
angiogenesis (61-62). It occurs in hypoxic areas and in areas with high metabolic 
demand and low perfusion. In hypoxic tissue, the initiation of angiogenesis arises 
from the production of angiogenic factors which upon binding with the receptors 
on the endothelial surface cause endothelial cell activation. Further proliferation 
and migration of activated cells into the surrounding matrix along with the 
degradation of ECM by MMPs allow formation of tubular outgrowths from the pre-
existing blood vessels. Finally, smooth muscle cells and pericytes stabilize these 
newly formed tubular structures to form a complete vascular structure (Figure 12) 
(63). As new capillaries sprout and increase in density, the distance between the 
adjacent vessels decrease causing increased diffusion, restoring oxygen and 
nutrient supply to the hypoxic tissue (62). The term "angiogenic switch" was 
introduced for a better representation of the initiation of angiogenesis depending 
on the availability of promoting factors and inhibiting factors (Figure 11) (64). 
Under normal physiological conditions, the regulation of angiogenesis 
occurs by a fine balance between growth promoting and inhibitory factors. An 
imbalance in these factors can result in increased angiogenesis as seen in 
cancer, or decreased angiogenesis as seen in myocardial ischemia or coronary 
artery disease. Previous studies demonstrate that the therapeutic angiogenesis 
using growth promoting factors can increase blood supply to the ischemic 
myocardium (65-67). Studies in cardiac specific inducible protein kinase B (AKT-
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1) transgenic mice show decreased angiogenesis during pathological remodeling 
and report that both heart size and cardiac function are angiogenesis dependent. 
The study further reported that the disruption of coordinated cardiac hypertrophy 
and angiogenesis plays a role in the pathogenesis of heart failure (68). 
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Figure 11: Representation of "angiogenic switch" mechanism. Under 
physiological conditions a balance exists between angiogenic and anti 
angiogenic factors ensuring normal angiogenesis (A). An imbalance in these 
factors results in the angiogenic switch turning 'ON' or 'OFF' (8). 
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Figure 12: Schematic representation of the mechanism of angiogenesis. 
A) Angiogenic factors produced during hypoxia bind to the receptors on the 
endothelial cells activating them. 8) Proliferation and migration of activated cells 
to form tube like structures. C) Smooth muscle cells provide structural support to 
these structures and thus stabilizing them into new functional blood vessel. 
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g) Angiogenic growth factors 
During hypoxia, transcription factors such as hypoxia-inducible factor 
(HIF-1) promote the synthesis of angiogenic growth factors (Table 3). Among 
these factors, vascular endothelial growth factor (VEGF) is a highly potent 
stimulator of capillary formation in vivo and has direct mitogenic actions on 
endothelial cells (62-63, 69-70). 
VEGF was first described in 1983 as a vascular permeability factor, which 
is secreted by tumor cells and induces vascular permeability (71). In 1989, cDNA 
cloning established that both vascular permeability factor and VEGF were the 
same molecule (70, 72). The up-regulation of VEGF mRNA during hypoxia 
shows that its production is induced to recruit blood vessels in ischemic tissue 
(73-74). VEGF binds to its receptors on the vascular endothelial cell surface. 
Tyrosine kinase receptors, Flt-1 and Flk-1 known as VEGF receptor-1 (VEGFR-
1) and VEGF receptor-2 (VEGFR-2) respectively, have strong affinity for the 
VEGF molecule (75-77). 
In the literature five types of VEGF are described, of which, VEGF-A is the 
key regulator of angiogenesis, VEGF-C and VEGF-D regulate 
Iymphangiogenesis (Figure 13) (74, 78-79). During myocardial ischemia, 
administration of angiogenic growth factor VEGF into the perivascular or 
intracoronary areas improves coronary collateral flow in animal models (80). 
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Table 3: Promoters and inhibitors of angiogenesis 
Endogenous angiogenic growth factors Endogenous inhibitors of angiogenesis 
Vascular endothelial growth factor MATRIX DERIVED: 
(VEGF) Angiogenin 
Angiopoietin-1 
Fibroblast growth factors: 
-acidic (aFGF) 
-basic (bFGF) 
Follistatin 
Hepatocyte growth factor (HGF) 
Interleukin-8 (IL-8) 
Placental growth factor 
Platelet-derived endothelial cell growth 
factor (PD-ECGF) 
Platelet-derived growth factor-BB 
(PDGF-BB) 
Pleiotrophin (PTN) 
Progranulin 
Proliferin 
Transforming growth factor-alpha 
(TGF-alpha) 
Transforming growth factor-beta (TGF-
beta) 
Tumor necrosis factor-alpha (TNF-
alpha) 
Endostatin 
Arresten 
Thrombospondin-1 and-2 
Tumstatin 
Canstatin 
Fibulin 
NON-MATRIX DERIVED: 
Angiostatin 
Parstatin 
Anti thrombin-III 
Interferons 
Interleukins 
Platelet factor 4 
OTHERS: 
Tissue inhibitor of MMPs (TIMP) 
Prolactin fragments 
Chondromodulin 
Troponin-I 
Vasostatin 
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Figure 13: Downstream effects of vascular endothelial growth factors (VEGF) 
following binding to their corresponding receptors (VEGFR). 
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h) Anti-angiogenic factors 
Anti-angiogenic factors are naturally produced as endogenous proteins, 
embedded in the matrix. Their release from the matrix regulate angiogenesis 
under physiological conditions (81). Endogenous angiogenic inhibitors are 
released by the action of MMPs and serine proteinases on ECM and vascular 
basement membrane (82). Although most of the angiogenic inhibitors are matrix 
derived, some are also fragments of ECM metabolites, hormones, clotting factors 
or proteins synthesized by the immune system (81, 83). While anti-angiogenic 
factors are extensively studied in cancer research, their role in cardiovascular 
disease is not well known (41, 48). Endostatin, arrestin, and tumstatin are some 
of the angiogenic inhibitors derived from the ECM. Angiostatin, interferons and 
antithrombin III are non-matrix derived anti-angiogenic factors (83). A list of 
endogenous anti-angiogenic factors is presented in Table 3. 
A recent study reports the relationship between angiostatin, endostatin 
and coronary collateral formation in which myocardial tissue is harvested from 
diabetic and nondiabetic coronary artery disease (CAD) patients (48). Results 
from the study show that the expression of angiostatin and endostatin increases 
in diabetic CAD patients compared with non-diabetic patients and negatively 
correlates with coronary collateralization. This data suggest the necessity of new 
approaches towards pro-angiogenic therapy or inhibition of anti-angiogenic 
mechanism in heart failure patients. 
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Endostatin 
Endostatin, first isolated by O'Reilly in 1997, is a 20-22 kDa C-terminal 
fragment of collagen type XVIII (Figure 14) (83-84). The direct actions of 
endostatin include, inhibition of vascular endothelial cell proliferation and 
migration, apoptosis, and cell cycle arrest at G1 stage of cell division (85-86). 
Indirectly, endostatin inhibits angiogenesis by blocking MMP-2 activity and 
preventing the binding of VEGF to its receptor (Figure 15). It also stabilizes cell to 
cell and cell to matrix adhesions preventing degradation of ECM junctions (87-
89). Although endostatin is extensively studied in cancer, its role in the 
pathogenesis of heart failure is not clear. In a study involving coronary heart 
disease patients, serum levels of endostatin are elevated along with the 
decreased coronary collateral formation (90). These results suggest that 
endostatin might play an important role in decreasing angiogenesis during 
decompensatory heart failure. 
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Figure 14: Formation of endostatin fragments from collagen XVIII by metal-
dependent cleavage, elastase and protease cleavage by cathepsin-L. 
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Figure 15: Mechanism of inhibition of angiogenesis byendostatin. 
HSPG-heperan sulfate proteoglycans; b FGF- fibroblast growth factor; a5~1-
integrin; Flk-1-VEGF receptor; FAK-focal adhesion kinase; ERK-extracellular 
signal regulated kinase. 
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Angiostatin 
Angiostatin is a proteolytic fragment of plasminogen, released by the 
action of matrix metalloproteinases. It is a 38kDa endogenous polypeptide that 
has inhibitory action on angiogenesis. It was first discovered by O'Reilly and 
colleagues in 1994 (91) and its structure consists of four Kringle domains (K1-4) 
(Figure 16) (92-93). Angiostatin inhibits angiogenesis by blocking the 
proliferation and migration of endothelial cells (Figure 17). The inhibitory action of 
angiostatin occurs through several mechanisms- a) blocking the integrins and 
angiomotin, preventing endothelial cell migration, b) binding to the a and ~ 
subunits of ATP synthase, reducing energy resources (93), c) blocking the 
actions of VEGF and bFGF on the vascular endothelial cells, and d) inhibiting 
the proliferation of vascular endothelial cells (VECs) by arresting mitosis at G2M 
transition (93-95). Angiostatin also promotes apoptosis of VECs by increaSing the 
tyrosine kinase activity of focal adhesion kinase (FAK) (96). Yamahara et aI., 
report elevated levels of angiostatin as well as MMP-9 activity, in the serum of 
heart failure patients (97). Their results suggest that angiostatin plays a 
pathological role in the progression of heart failure. 
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(K1-4) Angiostatin (K1-3) 
Figure 16: Formation of angiostatin from plasminogen (98) . tPA- tissue 
plasminogen activator; uPA- urikinase plasminogen activator; PGK-
phosphoglycerate kinase; K-Kringle domains of plasminogen . 
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Figure 17: Mechanism of action of Angiostatin. av~3- integrin. 
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i) Hydrogen sulfide 
Although hydrogen sulfide (H2S) was considered as a toxic gas with rotten 
egg smell, it has been recently recognized as a novel endogenous gaseous 
transmitter similar to nitric oxide (NO) and carbon monoxide (CO). H2S exerts 
various beneficial actions in the cardiovascular system (99-102). These three 
gaseous transmitters effectively dilate blood vessels through different 
mechanisms (Figure 18). H2S is an emerging gaseous transmitter of interest due 
to its protective role in brain, kidney, gastro intestinal tract, and more importantly, 
the cardiovascular system. H2S is endogenously generated by pyridoxal-5' 
phosphate dependent enzymes cystathione 13 synthase (CBS) and cystathione V 
lyase (CSE) using L-cysteine as a substrate (103). CBS is highly expressed in 
the brain whereas CSE is mostly found in the vasculature (104-105). A defect in 
CSE/H2S pathway is associated with many cardiovascular diseases suggesting 
its importance in physiological functions (106-111). 
Under physiological concentration, H2S exerts its cardioprotective effect by 
opening ATP sensitive potassium channels (K ATP channels) in vascular smooth 
muscle cells and as well as in the myocardium (107). The heart is considered to 
be one of the major sources of endogenous hydrogen sulfide, based on mRNA 
expression of CSE and amount of H2S generated (108). CSE knockout mice are 
profoundly hypertensive, indicating the vasodilatory role of H2S (112). Besides 
vasorelaxation, H2S promotes vascular endothelial cell related angiogenesis both 
invitro and in vivo. This action is based on opening of KATP channels that in turn 
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activate mitogen activated protein kinase (MAPK) pathway and AKT 
phosphorylation (113). 
The vasoprotective role of H2S is demonstrated in spontaneously 
hypertensive rats (SHR), by daily administration of sodium hydrosulfide (NaHS), 
a H2S donor, for 8 weeks (114). A significant reduction, in blood pressure, 
hypertrophy of intramyocardial arterioles, and ventricular fibrosis is observed with 
NaHS treatment (114). In addition, supplementation of H2S shows cardio 
protective effects in animal models of ischemia and myocardial infarction (115-
116). Based on these findings, we sought to examine the therapeutic effects of 
H2S during the transition from compensatory cardiac hypertrophy to heart failure. 
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Endothelial Cell 
Smooth muscle cell relaxation 
Figure 18: Mechanism of action of endogenous gaseous transmitters-nitric oxide 
(NO), hydrogen sulfide (H2S) and carbon monoxide (CO). All three gases cause 
vasorelaxation but by different mechanism of action. NO and CO act by 
activation of soluble guanylyl cyclase (sGC) and H2S acts by opening of 
potassium ATP sensitive (KATP) channels. CBS-cystathionine p synthase; NOS-
nitric oxide synthase; CSE-cystathionine y lyase; HO-1/2/3-heme oxygenase-
1/2/3; GTP-guanosine triphosphate; cGMP-cyclic guanosine monophosphate. 
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CHAPTER III 
HYPOTHESIS 
OVERALL HYPOTHESIS: Chronic pressure overload instigates compensatory 
cardiac hypertrophy, matrix remodeling (fibrosis), and increase in angiogenic 
growth factors. Persistent overload leads to an increase in anti-angiogenic 
factors resulting in decompensatory heart failure. Treatment with H2S mitigates 
the transition from compensatory hypertrophy to decompensatory heart failure by 
increasing angiogenesis and decreasing fibrosis. 
Specific aims: 
Hypothesis 1: A chronic increase in pressure overload induces MMP-2, which in 
turn, induces the release of angiogenic growth factors during the compensatory 
hypertrophy phase, while MMP-9fTIMP-3 releases anti-angiogenic factors during 
decompensatory heart failure phase. 
Aim 1: To determine whether chronic pressure overload induces MMP-2, which 
induces the release of angiogenic growth factors during compensatory cardiac 
hypertrophy. 
Aim 2: To determine whether MMP-9fTIMP-3 are induced during 
decompensatory heart failure and these in turn, induce the release of anti-
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angiogenic factors angiostatin and endostatin, during decompensatory heart 
failure. 
In chapter IV, experiments associated with Aims 1 and 2 are presented. 
Hypothesis 2: Treatment with H2S, during chronic pressure overload induces 
MMP-2 expression and inhibits MMP-9!TIMP-3 thereby, promoting angiogenesis 
which mitigates the transition from compensatory cardiac hypertrophy to heart 
failure. 
Aim 3: To determine whether the H2S induces MMP-2 expression and promotes 
the release of angiogenic growth factors, leading to angiogenesis. 
Aim 4: To determine whether the H2S inhibits MMP-9!TIMP-3 expression and 
blocks the release of anti-angiogenic factors, leading to a decrease in fibrosis. 
In chapter V, experiments associated with Aims 3 and 4 are presented. 
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Figure 19: Hypothetical representation of pressure overload heart failure and 
intervention by hydrogen sulfide. MMP-matrix metalloproteinase, TIMP-tissue 
inhibitor of matrixmetalloproteinase, VEGF-vascular endothelial growth factor, 
H2S-hydrogen sulfide. 
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ANIMAL GROUPS 
CONTROL H2S 
SHAM N=15 N=9 
AS 3 weeks N=12 N=8 
AS 8 weeks N=12 N=8 
Table 4 : Experimental animal groups used for the study. 
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CHAPTER IV 
MECHANISM OF TRANSITION FROM CARDIAC HYPERTROPHY TO HEART 
FAILURE 
The primary causes of heart failure are myocardial infarction, ischemia, 
and chronic pressure overload (i.e. systemic hypertension and valvular 
diseases). To overcome the initial stress, the heart undergoes compensatory 
hypertrophy and left ventricular remodeling (117). However, if the overload is 
sustained it results in decompensation and end-stage heart failure (118). During 
cardiac hypertrophy, there is an imbalance in the ratio of capillary bed to the 
cardiomyocytes, resulting in hypoxia, which increases the hypoxia-inducible 
factors (119). The hypoxia inducible factors stimulate the release of pro-
angiogenic factors, such as vascular endothelial growth factor (VEGF) (120-121). 
VEGF is a highly potent angiogenic factor that promotes endothelial cell 
proliferation, migration, extracellular matrix (ECM) remodeling and capillary 
formation (69, 122-125). These cellular events are essential processes of 
angiogenesis. The increase in production of VEGF and simultaneous decrease in 
anti-angiogenic factors, such as endostatin and angiostatin cause a net increase 
in angiogenesis (126). VEGF, fibroblast growth factor (FGF) and anti-angiogenic 
factors like angiostatin and endostatin, regulate the process of angiogenesis 
through activation of matrix metalloproteinases (MMPs) (42-43). 
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The transition from compensatory hypertrophy to decompensatory heart 
failure is regulated by discoordination of angiogenesis and hypertrophy during 
heart failure (68). Angiostatin and endostatin significantly inhibit tumor growth 
and vascularity in mice models by down regulating VEGF expression at both 
mRNA and protein levels (127). Interestingly, systemic administration of 
recombinant angiostatin and endostatin in tumor models demonstrates tumor 
regression by inhibition of angiogenesis (127). In another study on wound 
healing, endostatin suppresses ischemia induced neo-vascularization (128) and 
mediates its anti-angiogenic actions by inhibiting the function of pro-angiogenic 
molecules, such as VEGF receptor (89) and activation of MMPs (88). 
Alterations in cardiac gene expression during the transition from stable 
hypertrophy to heart failure elicit marked up-regulation of genes encoding ECM 
proteins (129-130). MMP-2 is constitutively expressed, and releases growth 
factors from the matrix during constitutive remodeling/hypertrophy/angiogenesis 
(46). MMP-9 is induced during heart failure (47) and generates cOllagen-matrix 
fragments; such as endostatin and angiostatin (48). TIMPs have various effects 
other than inhibiting MMPs. TIMP-1 induces fibrosis (131). TIMP-2 induces cell 
proliferation (132). TIMP-3 induces apoptosis (133). TIMP-4, a cardiac specific 
TIMP, induces apoptosis in transformed cells, but has no effect on normal cells 
(134). Although the role of pro-angiogenic and anti-angiogenic factors in the 
process of neo-vascularization is well-known; the differential role of these factors 
during the transition from compensatory cardiac hypertrophy to decompensatory 
heart failure remains obscure. The present work examines the role and 
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interaction of pro and anti-angiogenic factors during transition from compensatory 
hypertrophy to heart failure. We hypothesize that a chronic increase in pressure 
overload induces MMP-2, which in turn, induces the release of angiogenic growth 
factors during the compensatory hypertrophy phase while MMP-9fTIMP-3 
release anti-angiogenic factors during the decompensatory heart failure phase. 
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MATERIAL AND METHODS: 
Animals 
Wild type (WT, C57BL6/J) and MMP-9-/- (MMP-9KO) mice were obtained 
from Jackson Laboratories (Bar Harbor, Maine), housed in the animal care facility 
with access to water and standard chow. All animals were 12 weeks old and 
between 26-30 grams. All animal procedures were performed in accordance with 
National Institute of Health guidelines for animal research and were reviewed and 
approved by the Institute Animal Care and use Committee of University of 
Louisville. 
Pressure overload animal model 
Under pentobarbital anesthesia, (70mg/kg body weight dose, through 
intraperitoneal route) animals were intubated and ventilated. A left parasternal 
thoracotomy was performed and the ascending aorta is identified and dissected. 
Banding of the ascending aorta was done by placing a 26 g needle on the 
anterior surface of aorta and a 6-0 silk suture was then ligated around the aorta 
and the needle, and needle quickly removed resulting in constriction of aorta to 
create pressure overload on the heart (130). The thoracotomy was then closed in 
layers using 6-0 vicryl and 5-0 silk sutures for skin. Postoperative analgesia was 
given through intraperitoneal injection of keoprofen at the dose of 5mg/kg body 
weight for 48 hours. Sham animals underwent similar procedure except banding 
of aorta. To perform a longitudinal study, starting at time zero, all experimental 
results were compared with sham-operated mice at the same time post-surgery. 
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We compared mice at 3 and 8 weeks post-operation to their corresponding sham 
controls (n=5 per group). 
Left ventricular weight and body weight ratio (LV WtlBW) 
Animals were euthanized according to the IACUC protocol, and the 
hearts were excised, rinsed in phosphate buffer saline (PBS), and right and left 
ventricles were divided. Ratio of left ventricular weight and body weight was 
measured and represented in bar diagram (Figure 25). 
Antibodies and Reagents 
The following primary antibodies were used for protein analysis: rabbit 
polyclonal anti-angiostatin, mouse monoclonal anti-endostatin, rabbit polyclonal 
MMP-2, and rabbit polyclonal MMP-9. These antibodies were purchased from 
abcam (Cambridge, MA). Rabbit polyclonal antibody against VEGF (A-20), rabbit 
polyclonal antibody against TIMP-2, -3, and TIMP-4, and HRP-conjugated 
secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). 
Mouse monoclonal anti-GAPDH and all analytical reagents were from Sigma-
Aldrich (St. Louis, MO). 
Western blot analysis 
Heart tissue from mice was harvested and washed thoroughly in PBS and 
snap-frozen in liquid nitrogen. Protein extraction was done using 1 X RIPA buffer 
(Tris-HCI 50 mM,pH7.4; NP-40 1 %; Na-deoxycholate 0.25%; NaCI 150 mM; 
EDTA 1 mM; PMSF 1 mM; Na3V04 1 mM; NaF 1 mM; protease inhibitor cocktail 
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1 Jig/ml). Estimation of protein was done by Bradford method (Bio-Rad, Hercules, 
CA). 10-25 Jig of protein was fractionated by SOS-PAGE and transferred onto 
PVOF membrane (BioRad, Hercules, CA) by wet transfer method. The 
transferred proteins were processed for immunodetection of specific antigens. 
Briefly, non-specific sites were blocked with 5% non-fat dry milk in TBS-T (50 mM 
Tris-HCI, 150 mM NaCI, 0.1 % Tween- 20, pH 7.4) for 1 hour at room 
temperature. The blot was then incubated with appropriate primary antibody in 
blocking solution according to the supplier's specific instructions. The blots were 
washed with TBS-T (three times, 10 minutes each) and incubated with 
appropriate HRP-conjugated secondary antibody for 1 hour at room temperature. 
After washing, ECl Plus substrate (Amersham Biosciences, Pittsburgh, PA) was 
applied to the blot for 1 minute. The blot was developed using X-ray film (RPI 
Corp, Inc., Mount Prospect, Il) with a Kodak 2000A developer (Eastman Kodak, 
Rochester, NY). The blots were stripped and re-probed with GAPOH. The 
immuno-reactive bands were scanned and densitometrically analyzed by Un-
Scan-It software (Silk Scientific, Orem, UT). 
Echocardiography 
Two dimensional trans-thoracic echocardiography images of left ventricle 
from a four chambered apical view were taken with a phased-array 
echocardiography machine (SONOS 1500 or 2500; Hewlett-Packard, Inc.) using 
a 12.5-MHz transducer in anesthetized mice at baseline, 3 and 8 week post 
operation. Animals were given intraperitoneal injection of Tri-bromo ethanol 
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anesthesia (TBE) (135) at a dose of 240 mg per kilogram body weight, depilated 
and placed on a self regulating heating pad to maintain normal body 
temperature. Cardiac function, left ventricular internal dimension in diastole 
(LVIDd), left ventricular internal dimension in systole (LVIDs), left ventricular 
posterior wall dimension (LVPWD), and %Ieft ventricular fractional shortening 
(%FS) were assessed. 
Histological analysis of cardiac sections 
Frozen sections were cut at 8 ~m thickness using cryocut 1800 (Reichert-
Jung). Cryosections were placed on superfrost plus microscope slides and air 
dried. Histological analysis was done in all three groups using Masson's 
trichrome blue staining for detection of fibrosis, hematoxylin and eosin (H and E) 
staining for overall morphology. 
Immunohistochemistry 
Immunohistochemistry was performed on 5 ~m thick frozen sections of 
the heart using standard Immunohistochemistry (IHC) protocol. Anti-Endostatin 
(Abcam) and anti-TIMP-2, secondarily conjugated with Texas Red (Chemicon 
International, St. Charles, MO) were used for immunodetection of these two 
proteins, respectively. Anti-platelet endothelial cell adhesion molecule (PECAM) 
(also called CD31) clone-390, secondarily conjugated with FITC (Chemicon 
international, St.Charles, Missouri) was used to detect collateral density of micro-
vessels. 
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Coronary Angiograms 
Barium sulfate contrast coronary angiograms were done on excised 
hearts to visualize the differences in vascular density between all three groups of 
mice and MMP-9 Ko AB 8 weeks mice. Barium sulphate was mixed in 5.5 pH 
buffer and perfused via carotid artery into the heart at a constant flow rate using 
syringe pump (Chemyx Inc,Stafford,TX) and x-ray angiograms were taken with 
KODAK MM4000 mm imaging system (Carestream Health Inc, Rochester,NY). 
Pressure volume loop study (P-V loop) 
Using Millar Pressure-Volume system (Millar Instruments Inc, 
Houston,TX), following standard Millar protocol, steady state P-V loops were 
recorded followed by saline bolus and cuvette calibration for the conversion of 
RVU (relative volume units ) to ilL. Hemodynamic variables obtained were 
analyzed by PVAN software. The results were used to substantiate 
echocardiography findings. 
Statistical analysis 
All data were expressed as mean ± SE. Data were analyzed using a one-
way analysis of variance (ANOVA) to test for treatment effects, and differences 
between groups were determined using Tukey's post hoc test. A p value <0.05 
was considered significant. 
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Figure 20: Image showing an intubated mouse under ventilator support for the 
aortic banding procedure. 
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Figure 21: Photograph of mouse undergoing the aortic banding procedure. The 
segment of ascending aorta to be ligated is shown by arrow. 
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Figure 22: Image of barium contrast coronary angiogram in mouse using Kodak 
4000 MM image station. 
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RESULTS: 
Echocardiography data showed an increase in septal and left ventricular 
posterior wall thickness following 3 weeks of aortic banding (Figure 23). 
Fractional shortening was significantly decreased after 8 weeks of aortic banding 
compared with sham animals and/or mice 3 weeks post aortic banding. LVIDd 
increased after 3 weeks aortic banding and LVPWd increased after 8 weeks of 
aortic banding compared with sham controls. Interestingly, the left ventricular 
chamber size was increased after 8 weeks of aortic banding, suggesting that the 
heart had become dilated. The increase in ventricular wall thickness after 3 
weeks aortic banding suggests LV hypertrophy (Figure 23). These data 
demonstrate the transition from the compensatory phase observed at 3 weeks to 
decompensatory heart failure after 8 weeks of aortic banding. 
The P-V relationship data revealed that LV function was decreased after 
8 weeks of aortic banding in comparison with sham controls. Quantitative data 
obtained by P-V loop analysis, shows a decrease in ejection fraction and stroke 
volume after 8 weeks aortic banding. Also end systolic volume was increased 
after 8 weeks in comparison to sham controls (Figure 24). 
Gravimetric data revealed increase in LV weight/body weight ratio at 3 
weeks aortic banding and decrease at 8 weeks of aortic banding (Figure 25). 
These data suggest compensatory hypertrophy at 3 weeks and decompensatory 
heart failure at 8 weeks of aortic banding. To determine interstitial and 
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pericapillary fibrosis, trichrome-blue collagen histological staining was performed. 
Although basal level of collagen was detected in the sham group (Figure 26), 
there was increased collagen deposition at 3 weeks post aortic banding. The 
fibrosis was abundant at both the interstitial and epicardial regions of the hearts 
from 8 weeks aortic banding mice. 
MMPslTlMPs axis and angiogenic/anti-angiogenic factors in compensatory 
to decompensatory heart failure 
The expression of MMP-9 showed very little increase at 3 weeks aortic 
banding compared with sham (Figure 27). However, the expression was robust 
at 8 weeks post banding compared with either sham and/or 3 weeks banding. 
Contrary to MMP-9, MMP2 was increased at 3 weeks. Interestingly, this increase 
was almost normalized at 8 weeks post aortic banding (Figure 27). These results 
suggested a differential role of MMP-2 versus MMP-9 during transition from 
compensatory cardiac hypertrophy to decompensatory heart failure. 
The expression of TIMP-2 is decreased at 3 and 8 weeks, compared with 
sham control (Figure 28). However, a gradual decrease in TIMP-4 expression 
was observed from 3 weeks to 8 weeks post aortic banding (Figure 28). This 
suggested that TIMP-2 and TIMP-4 levels are decreased in decompensatory 
heart failure. 
Since TIMP-3 instigates apoptosis, we measured the levels of TIMP-3 
along with MMP-2, in situ. Although MMP-2 and TIMP-3 co-localized, contrary to 
TIMP-2ITIMP-4, the immunohistochemistry data revealed an increase in TIMP-3 
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levels at 3 weeks, however, interestingly, at 8 weeks of aortic banding hearts the 
decrease in TIMP-3 was robust (Figure 29). In situ data also revealed that MMP-
2 was elevated during 3 weeks with tendency to decrease at 8 weeks of aortic 
banding compared with sham (Figure 29). 
Since MMP-2 releases growth factors from the matrix and promotes 
angiogenesis, we measured the levels of angiogenic VEGF and anti-angiogenic 
(endostatin and angiostatin) levels. The levels of VEGF-A were increased in 3 
weeks group compared with sham controls (Figure 30). However, the expression 
of VEGF-A was diminished during 8 weeks post aortic banding, suggesting the 
decrease in angiogenic factors in decompensatory heart failure (Figure 30). The 
expression of anti-angiogenic factors like endostatin and angiostatin increased 
significantly at 8 weeks post aortic banding when compared with sham and/or 3 
weeks banding (Figure 30). The increase in expression of endostatin at 8 weeks 
aortic banding was further evidenced by immunohistochemical staining (Figure 
31 ). 
Angiogenesis/vasculogenesis 
The CD31 staining (an endothelial cell marker) showed increased density 
of endothelial cells during 3 weeks compared with sham and 8 weeks aortic 
banding groups, suggesting increased endothelial cell density (Figure 32). 
Interestingly, staining with CD31 also visualized the capillary density, 
represented by endothelial cells density and was also increased at 3 weeks 
compared with sham or 8 weeks aortic banding. 
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To corroborate CO-31 endothelial/capillary data with vasculogenesis, we 
performed in vivo real-time soft-tissue x-ray angiography using barium as 
contrasting agent. The angiography data showed increased in vascular density at 
3 weeks aortic banding; whereas capillary rarefaction was observed at 8 weeks 
post aortic banding (Figure 33). To determine the role of MMP-9 as inducers of 
anti-angiogenic factors (endostatin and angiostatin), we created aortic banding in 
MMP-9-/- (MMP-9KO) mice. The results suggested increase in vascular density 
in MMP-9KO after 8 weeks aortic banding compared with sham controls (Figure 
33). 
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Figure 23: Aortic banding induced changes in cardiac function 
Panels represent M-mode echocardiography of sham (8 weeks) , 3 weeks 
and 8 weeks after aortic banding. The bars graphs represented percentage of 
fraction shortening (FS) , LVIDd (left ventricular internal dimension in diastole), 
and LVPWd (left ventricular posterior wall dimension in diastole). *p<O.05 
compared with sham. Data are mean ± SE; n = 5/group 
64 
7 
60 .Sham 
. 8wks 
50 
40 
30 
20 
10 
Figure 24: Changes in cardiac function due to aortic banding 
Pressure-volume loop by Millar catheter of sham and 8 weeks aortic 
banding mice: The bar graphs depict % ejection fraction (EF), ESV (End systolic 
stroke volume) ,' and stroke volume (SV) in sham and 8 weeks aortic banding 
mice. Data are mean ± SE; n=5/group *p<O.05 vs sham. 
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Figure 25: Aortic banding increase cardiac mass. 
A) The gross images of the whole heart of sham, 3 weeks, and 8 weeks 
aortic banding. Hearts were cleaned in phosphate buffered saline. The left 
ventricle was separated. B) The ratio of left ventricle (LV) weight (wt) to body 
weight (BW) was depicted in bar graph. Data are mean ± SE; n=51 group. 
*p<O.01 vs sham. 
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Figure 26: Aortic banding induced changes in cardiac morphology 
Representative microphotographs of Masson's-trichrome blue histological 
staining of frozen heart sections: The hearts from sham, 3 weeks, 8 weeks and 
MMP-9 KO 8 weeks aortic banding were analyzed. Arrow indicates endocardial 
and peri-capillary fibrosis . 20 x magnifications. The insert box, 100 x 
magnifications. 
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Figure 27: Western blot analyses of MMP-9 and MMP-2 expression in Sham, 3 
weeks and 8 weeks of aortic banding: Bar graphs showed densitometric analysis 
of MMP-9 and MMP-2 expression over sham groups (protein normalized with 
GAPDH). Each bar represents mean ± SE, *p<O.05 vs sham, ** compared with 3 
weeks, from n=5 in each group. The percent protein expression on Y-axis is the 
protein expression calculated as fold change vs. sham. 
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Figure 28: Western blot analyses of TIMP-2 and TIMP-4 expression in Sham, 3 
weeks and 8 weeks of aortic banding: Bar graphs showed densitometric 
analyses of TIMP-2 and TIMP-4 expression over sham groups (protein 
normalized with GAPDH). Each bar represents mean ± SE, *p<O.05 vs sham, ** 
compared with 3 weeks, from n=5 in each group. The percent protein expression 
on Y-axis is the protein expression calculated as fold change vs. sham. 
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Figure 29: Left ventricle Immunohistochemical staining and co-localization of 
TIMP-3 and MMP-2: Cryocut frozen sections of (8-10 J..lm) were stained and 
secondarily conjugated with FITC for TIMP-3 and texas red for MMP-2 (white 
arrows indicate capillaries). The bar diagrams depicted the intensity 
quantification of TIMP-3 and MMP-2 by Fluoview software, in sham, 3 weeks and 
8 weeks aortic banding. Data presented mean ± SE; *p<O.01 vs sham; **p<O.05 
vs 3 weeks; n=5 animals per group. 
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Figure 30: Measurement of angiogenic and anti-angiogenic factors: Western blot 
analyses of VEGF-A, endostatin and angiostatin. Bar graphs showed the relative 
expression of VEGF-A, endostatin , and angiostatin over sham group (after 
normalization with GAPDH). The data presented mean ± SE, *p<O.05 vs sham; 
**, compared with 3weeks. The percent protein expression on Y-axis is the 
protein expression calculated as fold change vs. sham. 
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Figure 31: Immunohistochemical staining of endostatin. Cryocut frozen tissue 
sections (5 11m) are stained with anti-endostatin antibody secondarily conjugated 
with Texas red dye. Nuclei are stained with DAPI. Bar diagrams depicted 
intensity quantification by image pro-software. Each bar representative mean ± 
SE, **p<O.05 vs sham or 3 weeks, n=5 animals/group. 
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Figure 32: Immunohistochemical staining with CD31 (PECAM) in sham, 3 weeks 
and 8 weeks aortic banding groups. DAPI was used for nuclear staining. The 
images were merged. The arrows point to capillary structure. Bar diagrams 
represent quantified arbitrary number of CD 31 staining endothelial cell in 
capillaries per each field randomly selected with the help of Image-Pro software. 
The data presented mean±SE, n=51 group. *p<O.01 vs Sham; **p<O.05 vs 3 
weeks. 
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Figure 33: Barium-contrast x-ray angiograms, to demonstrate gross variability in 
vasculature among sham, 3 weeks, 8 weeks and MMP-9KO (at 8 weeks). In vivo 
hearts were perfused with Barium sulfate solution and x-ray imaging was taken 
with KODAK MM4000 both in whole body and in isolated hearts. The bar 
diagrams depicted quantified intensity of the images from randomly chosen areas 
of same size, with Image-J software. The data presented mean±SE, *p<O.05 vs 
sham; **p<O.01 vs 3 weeks; ***, compared with 8weeks. n=5 animals per group. 
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Figure 34: Hypothetical presentation of latent MMP activation under chronic 
oxidative load condition. The imbalance in MMP/ TIMP axis and remodeling, 
generating angiogenic, anti-angiogenic, factors, leading to apoptosis and chronic 
heart failure (CHF). Abbreviations: ROS, reactive oxygen species; RNS, reactive 
nitrogen species; RTS, reactive thiol species; NADH, nicotinamide adenine 
dinucleotide (reduced); SOD, superoxide dismutase; Prx, peroxiredoxin; VEGF, 
vascular endothelial growth factor; ADAM, a disintegrin and metalloproteinase; 
Meprins, metalloproteinase in renal; iNOS, inducible nitric oxide synthase; eNOS, 
endothelial nitric oxide synthase; GSSG/GSH, oxidized glutathione/reduced 
glutathione; MT-MMP, membrane type-MMP. 
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Discussion: 
Systemic hypertension causing left ventricular pressure overload, is one of 
the leading risk factors of cardiac hypertrophy that eventually leads to heart 
failure. These hypertrophied hearts exhibit contractile dysfunction, dilation of the 
ventricular wall and increased wall thickness (136). In the normal human heart, 
after acute ischemic injury, LV wall stress increases, whereas wall thickness and 
ejection fraction decreases. To compensate for the overload, the entire 
myocardium undergoes compensatory hypertrophy/remodeling, Le; enlargement 
of the muscle tissue and remodeling of the entire chamber. The ejection fraction 
and wall thickness decreased significantly during decompensatory phase, though 
it is maintained near normal level during compensatory phase (17). Our studies 
suggest that there is an increase in MMP-2, decrease in TIMP-2 and -4, increase 
in angiogenic factors and vascularization in compensatory hearts. However, in 
decompensatory hearts there was an increase in MMP-9, TIMP-3, endostatin, 
angiostatin, and vascular rarefaction. The increased expression of VEGF-A 
during 3 weeks post aortic banding showed the importance of angiogenesis 
during hypertrophy. There was an increase in the expression of angiostatin and 
endostatin in the 8 weeks post aortic banding. These data suggest that higher 
levels of angiogenic factors provide impulse for cardiac compensation while up-
regulation of anti-angiogenic factors promotes decompensatory heart failure. 
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During angiogenesis, increased expression of VEGF was associated with 
a simultaneous decrease in anti-angiogenic factors, such as endostatin and 
angiostatin. Endostatin is derived from collagen XVIII, inhibits angiogenesis (84) 
and induces endothelial cell apoptosis (85, 137). Angiostatin is a cleavage 
product of plasminogen. Angiostatin is reported to induce endothelial cell death 
(138-140), inhibits endothelial cell proliferation, (141) migration and tube 
formation (142). Our study demonstrated that increased capillary density, as 
evidenced by increased endothelial cell population, was observed during 3 
weeks of aortic banding, and this was supported by the evidence of up- regulated 
VEGF-A and basal level of endostatin and angiostatin expression. Conversely, 
during decompensatory heart failure (8 weeks aortic banding), VEGF-A was 
diminished and up regulation of endostatin and angiostatin was observed 
resulting in a decrease in capillary density. 
The endogenous inhibitors of MMPs, TIMPs, inhibit MMP activity; 
therefore, the balance of MMPsfTlMPs is very important in order to maintain 
normal physiological matrix architecture (143). MMP-2 and 9 both are able to 
cleave collagen and play a major role in ECM remodeling. During cardiac 
hypertrophy and chronic heart failure, the imbalance of MMPsfTlMPs caused 
changes in matrix composition, resulting in cardiac fibrosis. TIMP-2 and TIMP-4 
inhibit both MMP-2, and -9, and therefore, a decrease in TIMP-2 and TIMP-4 
augments MMP-2 and -9 activities that promote cardiac fibrosis. The results of 
this study show that increased fibrosis was observed at 8 weeks post aortic 
banding. This is consistent with up regulation of MMP-9. Interestingly, an up 
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regulation of MMP-2 was observed at 3 weeks and a down regulation of MMP-2 
was observed in 8 weeks aortic banding. This suggests possible differential 
regulation of these two MMPs by TIMP-2 and TIMP-4 during compensatory 
cardiac hypertrophy leading to decompensatory heart failure. Moreover, TIMP-3 
expression increased at 3 weeks and continued to increase at 8 weeks aortic 
banding. This may suggest TIMP-3 associated cell death (133). 
In conclusion, our study showed that pressure overload cardiac 
hypertrophy was compensated with increased angiogenesis and MMP-2, 
whereas decompensatory heart failure was accompanied with an increase in 
MMP-9 and TIMP-3, resulting in non-specific collagen cleavage and up 
regulation of potent antiangiogenic factors that eventually led to heart failure 
(Figure 34). The novelty of this study was the mechanistic disconnect between 
angiogenesis/hypertrophy in compensatory heart to anti-
angiogenesis/hypertrophy in decompensatory heart failure. 
Limitations: Although we do not have a direct connection as to whether the 
MMP-2 releases angiogenic factors and MMP-9/TIMP-3 releases anti-angiogenic 
factors in stressed hearts, we show data that the levels of MMP-2 and -9, TIMP-
2, -3 and -4, VEGF, angiostatin and endostatin are modified in the direction 
suggested by the hypothesis, which suggests a causal relationship. With 
immuno-Iabeling, presumably, we detected both inactive pro and active MMP-2. 
Also, the histochemical data shown in Figure 29 detected total active and pro 
MMP-2. However, without a change in active MMP-2, we cannot infer specifically 
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that MMP-2 elevation was responsible for the pro-angiogenic changes at 3 
weeks. Because the blood flow in coronary arteries was pulsatile, we may be 
unclear whether we really estimated the vascular density by measuring black 
pixels. However, we have taken the images of the heart in diastole using KCI at 
the same time of cardiac cycle. In MMP-9KO mice, the amelioration of cardiac 
dysfunction in many cardiac disorders were already demonstrated (144-146), 
here we showed that in the MMP-9 KO AB 8 weeks mice, there was absolute 
decrease in fibrosis (Figure 26), and also there was an increase in vascular 
density (Figure 33). 
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CHAPTER V 
ROLE OF HYDROGEN SULFIDE DURING TRANSITION FROM CARDIAC 
HYPERTROPHY TO HEART FAILURE 
Introduction: Cardiovascular disease (CVD) is the leading cause of death for 
both men and women. Hypertension is the major risk factor of CVD (1). Although 
initial pressure overload during hypertension is compensated by cardiac 
hypertrophy, sustained overload results in progression towards heart failure due 
to an imbalance in myocyte-capillary ratio (15, 147). In previous studies we 
demonstrated that during the compensatory hypertrophy phase, MMP-2 is 
induced and leads to the production of angiogenic growth factors like VEGF and 
promotes angiogenesis. In later stages of compensatory hypertrophy, MMP-9 
and TIMP-3 are induced and play a significant role in the production of anti-
angiogenic growth factors like endostatin and angiostatin. This leads to apoptosis 
and causes transition from compensatory cardiac hypertrophy to 
decompensatory heart failure (41). Recent studies report that the endogenous 
gaseous transmitter, hydrogen sulfide (H2S) plays an important role in cardiac 
protection during ischemia, infarction and heart failure (108, 116, 148-149). H2S 
is endogenously generated by pyridoxal-5' phosphate dependent enzymes, 
cystathione ~ synthase (CBS) and cystathione V lyase (CSE) using L-cysteine as 
a substrate (103). CBS is highly expressed in the brain whereas CSE is mostly 
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found in vasculature (104-105). H2S promotes vascular relaxation and also has a 
negative inotropic effect on cardiac muscle. Both effects are attributed to the 
ability of H2S to open potassium sensitive ATP channels (KATP), which are widely 
distributed in coronary vasculature and myocardium (150). Studies quantify the 
expression of CSE in the heart and correlate it with levels of H2S. The results 
suggest that the heart is one of the major sources of endogenous H2S (108). 
Mutant mice lacking CSE exhibit pronounced hypertension and diminished 
endothelium dependent vasorelaxation (112). This provides evidence that H2S is 
a physiological vasodilator and regulator of blood pressure. Exogenous 
supplementation of H2S decreases medial thickening of intracardiac coronary 
vessels and reduced interstitial fibrosis in spontaneously hypertensive rats, 
suggesting that H2S increases the coronary reserve in hypertrophied hearts 
(114). Hypertrophied hearts are protected against severe ischemia by promoting 
angiogenesis (151). In vitro, VEGF causes an increase in H2S release in 
endothelial cells while pharmacological inhibition of H2S production or KATP 
channels attenuates VEGF signaling and EC migration (113). The pro-angiogenic 
effect of H2S involves the signaling mechanism via AKT phosphorylation and 
activation of the MAPK pathway (152). 
MMPs and their natural endogenous inhibitors, TIMPs are predominantly 
present in the heart and their expression is upregulated under pathological 
conditions (153). MMP-2 and MMP-9 are the two important gelatinases that play 
an important role in the development and remodeling of the heart and 
vasculature (154). Previous studies report that MMP-2 plays a significant role in 
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angiogenesis and heart valve development (155-156). Knockout mice deficient in 
MMP-2 have various anomalies of the heart during embryogenesis (42, 46, 157-
158). Brooks and colleagues report that an angiogenic stimulus induces vascular 
remodeling through activation of MMP-2 and integrin (av~3) (44-45). Although 
previous studies report that the MMP-2 expression and activity were significantly 
elevated in VEGF treated hypertrophied hearts (42), only few studies have 
examined the role of endostatin and angiostatin in heart failure (41, 48). We 
previously reported that MMP-9 induces endostatin and angiostatin production, 
which contribute to transition towards the decompensatory phase of heart failure 
(41). Studies in MMP-9 knockout mice have shown attenuation of ventricular 
enlargement, collagen deposition, and facilitation of angiogenesis following 
experimental myocardial infarction (144-145, 159). There is evidence that TIMP-3 
plays an important role in inducing apoptosis as well as inhibiting angiogenesis 
(41, 58, 133) . The purpose of this study was to determine whether H2S could 
mitigate the transition from compensatory cardiac hypertrophy to heart failure. 
We hypothesize that H2S induces MMP-2 expression and inhibits MMP-9!TIMP-3 
expression, thereby promoting angiogenesis which mitigates the transition from 
compensatory cardiac hypertrophy to heart failure. 
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MATERIAL AND METHODS 
Animals 
Wild type mice (WT, C57BL6/J) aged 8 weeks were obtained from 
Jackson Laboratories (Bar Harbor, Me.; USA) and housed in the animal care 
facility at University of Louisville with access to standard chow and water. At the 
age of 12 weeks with an approximate weight of 23-25 grams, animals underwent 
pressure overload aortic banding (AB) surgery and divided into 2 groups: one 
group received 30 Ilmol/liter of sodium hydrogen sulfide (NaHS) in the drinking 
water and other received plain water (untreated control). Each group was further 
subdivided into sham, 3 weeks after AB surgery (AB 3 weeks group) and 8 
weeks after AB surgery (AB 8 weeks group) with respect to the time points they 
attain hypertrophy and heart failure. 6 animals per group was used (n=6). After 
the study period, animals were euthanized in accordance with National Institute 
of Health Guidelines for animal research. The protocol was reviewed and 
approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of Louisville. 
Pressure overload animal model 
Animals were anesthetized with sodium pentobarbital, intubated and 
ventilated with Harvard mini ventilator. Body temperature was maintained with a 
heating pad (TR 200, Fine Science Tools, Foster City, CA). Under sterile 
conditions the thorax was opened by left parasternal thoracotomy, and the 
ascending aorta was dissected and separated from adjacent structures. Care 
83 
was taken to maintain proper hemostasis. Aortic banding was performed by 
placing a 26 g needle on the aorta and ligating around the vessel with 6-0 silk. 
The needle was quickly removed to keep the constricted aorta patent. The 
induced pressure overload effectively produced LV hypertrophy within 3 weeks 
after AB. The wound was closed in layers using 6-0 vicryl for subcutaneous 
tissues and 5-0 silk for the skin (130). All animals received intraperitoneal 
injection of Ketofen, 5 mg/Kg body weight for post operative analgesia. Animals 
in the sham subgroups underwent similar procedures except aortic banding. 
Hydrogen sulfide treatment 
Animals were given 6 weeks of H2S in the drinking water in the form of 
NaHS (Sigma), which in aqueous solution releases H2S. A 30 Ilmoi/liter 
concentration was supplemented to keep the hydrogen sulfide in physiological 
range (10-100 Ilmol/l). The diffusion of H2S into room air is minimal since its 
density is 18% higher than that of air. Furthermore the drinking water was 
changed daily with fresh NaHS solution to provide adequate levels of H2S to the 
mice (160). 
Antibodies and Reagents 
The following primary antibodies were used for studies: rabbit polyclonal 
anti-angiostatin, mouse monoclonal anti-endostatin, rabbit polyclonal MMP-2, 
and rabbit polyclonal MMP-9, rabbit polyclonal antibody against TIMP-3; (Abcam, 
Cambridge, MA); anti-mouse VEGF antibody ( R&D systems, Minneapolis, MN) 
and mouse monoclonal anti-GAPDH (Sigma-Aldrich, St. Louis, MO). 
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Following fluorescent secondary antibodies for Immunohistochemistry 
(IHC) were ordered from Invitrogen (Carlsbad, CA), Texas Red raised in mouse 
and Alexa Fluor 488 and 594 raised in rabbit. 
Western blot analysis 
Heart tissue from experimental animals and control animals was 
harvested and washed thoroughly in PBS and snap-frozen in liquid nitrogen. 
Protein extraction was done using 1 X RIPA buffer (Tris-HCI 50 mM, pH7.4; NP-
40 1 %; Na-deoxycholate 0.25%; NaCI 150 mM; EOTA 1 mM; PMSF 1 mM; 
Na3V04 1 mM; NaF 1 mM; protease inhibitor cocktail 1 I1g/ml). Estimation of 
protein was done by BCA method (Thermo fisher, Pittsburgh, PA). 50-75 I1g of 
protein was fractionated by SOS-PAGE and transferred onto PVOF membrane 
(BioRad, Hercules, CA) by wet transfer method. The transferred proteins were 
processed for immunodetection of specific antigens. Briefly, non-specific sites 
were blocked with 5% nonfat dry milk in TBS-T (50mM Tris-HCI, 150mM NaCI, 
0.1% Tween- 20, pH 7.4) for 1h at room temperature. The blot was then 
incubated with appropriate primary antibody in blocking solution according to the 
supplier's specific instructions. The blots were washed with TBS-T (3 times, 10 
min each) and incubated with appropriate HRP- conjugated secondary antibody 
for 1 h at room temperature. After washing, ECl Plus substrate (Amersham 
Biosciences, Pittsburgh, PA) was applied to the blot for 1 min. The blot was 
developed using BIO-RAO Chemi Doc XRS + (BIO-RAO laboratories, Hercules, 
CA). The blots were stripped and re-probed with GAPOH. The immuno reactive 
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bands were scanned and densitometry analyzed by Un-Scan-It software (Silk 
Scientific, Orem, UT). 
Echocardiography 
Transthoracic echocardiography was performed on mice to achieve two 
dimensional left ventricle images from an apical view using a SONOS 1500 or 
2500; Hewlett-Packard, Inc. and a 12.5 MHz transducer. The procedure was 
performed as previously published (41) using tribromo ethanol (TBE) anesthesia 
to minimize the cardio depressing actions produced by other anesthetics (135). 
First mice were anesthetized with intraperitoneal injection of TBE,(240 mg/kg 
body weight dose), depilated with hair removal cream (Nair) and placed on a 
heating pad to maintain body temperature. The functional status of the heart was 
assessed by LVIDd, LVIDs, LVPWD and %FS. In murine echocardiography %FS 
is the most common method to evaluate left ventricular function (161). 
Cryosectioning 
After mice were euthanized, hearts were harvested and thoroughly 
washed in PBS and preserved in Peel-A-Way disposable plastic tissue 
embedding moulds (Polysciences inc., Warrington, PA.,USA) filled with tissue 
freezing media (Triangle Biomedical Sciences, Durham, N.C., USA) and stored 
at 0700 C until analysis. Tissue sections 5 11m in thickness were made using 
Leica CM 1850 Cryocut (Bannockburn, IL, USA). Sections were placed on Super 
frost plus glass slides, air-dried and processed for histological and 
Immunohistochemistry (IHC) staining. 
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Immunohistochemistry 
Immunohistochemistry was performed on 5 11m thick frozen tissue 
sections using a standard IHC protocol (Abcam). Primary antibodies applied 
overnight and included anti-endostatin, anti-TIMP-3 (Abcam) and VEGF antibody 
(R&D). A secondary antibody labeled with Texas Red (Invitrogen) was applied for 
immunodetection of these proteins. Similarly, primary antibodies anti-MMP-2 and 
anti-MMP-9 (Abcam) were applied overnight and secondarily conjugated with 
Alexa fluor 488 (Invitrogen) to detect expression of these MMPs. Stained slides 
protocol slides were analyzed for fluorescence using a laser scanning confocal 
microscope (Olympus FluoView1000) set at the appropriate filter settings. 
Masson's Trichrome Staining 
Collagen expression in tissue sections was assessed by Masson's 
trichrome staining according to the manufacturer's instructions (Richard-Allan 
Scientific, Kalamazoo, MI., USA). Collagen identified as blue staining. 
Image Proplus software 
Images from Immunohistochemistry and Masson's trichrome staining were 
analyzed with Image Proplus software. 
Pressure volume loop study (P-V loop) 
To assess the left ventricular function, pressure-volume study was done 
using Millar Pressure-Volume system (Millar Instruments Inc, Houston,TX). 
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Following standard Millar protocol, steady state P-V loops were recorded 
followed by saline bolus and cuvette calibration for the conversion of RVU 
(relative volume units) to ilL. Hemodynamic variables obtained were analyzed by 
pressure volume analysis (PVAN) software. The results were used to 
substantiate echocardiography findings. % ejection fraction (%EF) was used to 
assess the functional status of the left ventricle. 
Statistical analysis 
All data are expressed as mean ± SE. Data were analyzed using a one-
way analysis of variance (ANOVA) to test for treatment effects, and differences 
between groups were determined using Tukey's post-hoc test. A p value <0.05 
was considered to be significant. 
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RESULTS 
To determine the effects of H2S on minimizing the remodeling of heart in a 
pressure overload mouse model, LV function was evaluated. Echocardiography 
data showed a decreased in left ventricular chamber diameter in H2S treated AB 
3 weeks group and AB 8 weeks group compared to untreated controls. These 
findings suggest that dilatation of the heart decreases with H2S treatment (Figure 
35). The %FS and the %EF of the heart, representing ventricular function, were 
significantly improved in AB 3 weeks and AB 8 weeks H2S treated groups 
compared to untreated controls (Figure 36). 
Tissue sections were analyzed for changes in fibrosis content following 
AB. Interstitial and perivascular collagen deposition analysis demonstrated an 
increase in fibrosis after 8 weeks of AB in comparison to sham controls and 
animals 3 weeks post-AB. Collagen deposition was significantly reduced in H2S 
treated animals at 3 and 8 weeks post-AB compared to untreated controls 
(Figure 37). These findings suggest that H2S decreases vascular resistance and 
reduces the effect of pressure overload on heart. 
To assess the effect of H2S on angiogenesis, VEGF was quantified in 
tissue sections by IHC and by Western blot analysis. VEGF expression 
significantly increased in H2S-treated animals at 8 weeks post-AB compared to 
untreated controls (Figures 39 and 49). 
To assess the effect of H2S on the transition from compensatory to 
decompensatory heart failure, anti-angiogenic factor levels were quantified. 
Endostatin and angiostatin levels increased in untreated controls, 8 weeks post 
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AB compared to sham and in animals 3 weeks post AB. Increasing levels of 
endostatin and angiostatin suggest that post-AB angiogenesis at 8 weeks 
. 
decreased and led to decompensatory heart failure. H2S treatment significantly 
reduced the expression of endostatin and angiostatin in 8 weeks post-AB 
animals, compared with untreated control at 8 weeks. These results suggest the 
inhibitory action of H2S on anti-angiogenic factors endostatin and angiostatin 
(Figures 41 and 49). 
To assess the effect of H2S on the MMPrrlMP axis in heart failure, 
expression of MMP-2, -9, and TIMP-3 levels were quantified. MMP-2 expression 
increased in untreated mice 3 weeks post-AB compared to sham and 8 weeks 
post-AB mice. Expression of MMP-9 and TIMP-3 increased in untreated mice 8 
weeks post-AB compared to sham and 3 weeks post-AB mice. H2S treatment 
increased the expression of MMP-2 after 8 weeks post-AB compared to 
untreated controls of same group (Figures 43 and 50). In contrast, H2S treatment 
decreased the expression of both MMP-9 and TIMP-3 at 8 weeks post-AB 
compared to untreated controls at 8 weeks (Figures 45,47 & 50). These findings 
suggest the beneficial effect of H2S is associated with the inhibiton of anti-
angiogenic factors, controlled by the MMPrrlMP axis. 
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Sham AB 3 weeks ~eks 
Figure 35: Changes in left ventricular (LV) function following aortic banding (AB) 
and the effects of hydrogen sulfide (H2S) treatment. Representative M-mode 
echocardiography images from sham group, AB 3 weeks and AB 8 weeks group. 
The effect of H2S on LV function is shown in lower panel. Arrows show the 
differences in LV internal diameter between treated and untreated animals 
compared to their corresponding controls. 
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Figure 36: The bar graphs represent %FS and %EF obtained by 
echocardiography and pressure-volume loop study. Each bar represents mean ± 
SE, n=6 per group. *p <0.05, considered as siginificant. 
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Sham AB 3 wks AB 8 wks 
Control 
Figure 37: Masson's trichrome blue staining of collagen depicting intracardiac 
and perivascular fibrosis . Top panel represents heart sections from untreated 
sham, 3 weeks post-AS (AS 3 wks) and 8 weeks post-AS (AS 8 wks) groups. 
Sottom panel shows the corresponding groups treated with hydrogen sulfide 
(H2S). 
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Figure 38: Quantification of collagen (blue staining) was done with the help of 
Image proplus software and represented in bar diagram. Data represents mean ± 
SE from n=6 per group; *p<O.05 considered as significant. 
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Control 
Figure 39: Immunohistochemical (IHe) staining of heart sections with vascular 
endothelial growth factor (VEGF) , secondarily stained with alexaflour 594 in 
sham, 3 weeks post-AB (AB 3 wks) and 8 weeks post-AB (AB 8 wks) in the top 
panel and corresponding H2S treated groups in the bottom panel. The expression 
of VEGF is seen as red fluorescence intensity. 
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Figure 40: Quantification of VEGF stained heart sections in sham, 3 weeks after 
aortic banding (AS 3 wks) , and 8 weeks after aortic banding (AS 8 wks) in 
untreated controls and their corresponding hydrogen sulfide (H2S) treated 
groups. Data represents mean ±SE from n=6 per group; *p<O.05 was 
considered significant. 
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Figure 41: Immunohistochemical (IHe) staining of heart sections with endostatin , 
secondarily stained with texas red fluorescent antibody in sham, 3 weeks post-
AS (AS 3 wks) and 8 weeks post-AS (AS 8 wks) in the top panel and 
corresponding H2S treated groups in the bottom panel. The expression of 
endostatin is seen as red fluorescence intensity. 
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Figure 42: Quantification of endostatin stained heart sections in sham, 3 weeks 
after aortic banding (AB 3 wks) , and 8 weeks after aortic banding (AB 8 wks) in 
untreated controls and their corresponding hydrogen sulfide (H2S) treated 
groups. Data represents mean ±SE from n=6 per group; *p<O.05 was 
considered significant. 
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Sham AB 3 wks AB 8 wks 
Control 
Figure 43: Immunohistochemical (IHe) staining of heart sections with MMP-2 
antibody, secondarily stained with alexaflour 488 fluorescent antibody in sham, 3 
weeks post-AB (AB 3 wks) and 8 weeks post-AB (AB 8 wks) in the top panel and 
corresponding H2S treated groups in the bottom panel. The expression of MMP-2 
is seen as green fluorescence intensity. 
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Figure 44: Quantification of MMP-2 stained heart sections in sham, 3 weeks 
after aortic banding (AB 3 wks) , and 8 weeks after aortic banding (AB 8 wks) in 
untreated controls and their corresponding hydrogen sulfide (H2S) treated 
groups. Data represents mean ±SE from n=6 per group; *p<O.05 was 
considered significant. 
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Figure 45: Immunohistochemical (IHe) staining of heart sections with MMP-9 
antibody, secondarily stained with alexaflour 488 fluorescent antibody in sham, 3 
weeks post-AB (AB 3 wks) and 8 weeks post-AB (AB 8 wks) in the top panel and 
corresponding H2S treated groups in the bottom panel. The expression of MMP-9 
is seen as green fluorescence intensity. 
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Figure 46: Quantification of MMP-9 stained heart sections in sham, 3 weeks 
after aortic banding (AB 3 wks) , and 8 weeks after aortic banding (AB 8 wks) in 
untreated controls and their corresponding hydrogen sulfide (H2S) treated 
groups. Data represents mean ±SE from n=6 per group; *p<O.05 was 
considered significant. 
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Figure 47: Immunohistochemical (IHe) staining of heart sections with TIMP-3, 
secondarily stained with texas red fluorescent antibody in sham, 3 weeks post-
AB (AB 3 wks) and 8 weeks post-AB (AB 8 wks) in the top panel and 
corresponding H2S treated groups in the bottom panel. The expression of TIMP-3 
is seen as red fluorescence intensity. 
103 
50 
S 40 
-< 
'-' 30 ~ 
... 
...... 
~ 20 
aJ 
... 
~ 10 
o 
* * 
Figure 48: Quantification of TIMP-3 stained heart sections in sham, 3 weeks 
after aortic banding (AB 3 wks) , and 8 weeks after aortic banding (AB 8 wks) in 
untreated controls and their corresponding hydrogen sulfide (H2S) treated 
groups. Data represents mean ±SE from n=6 per group; *p<O.05 was 
considered significant. 
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Figure 49: Western blot analysis of VEGF-A, angiostatin and endostatin 
expression in sham, 3 weeks after aortic banding (AB 3 wks) and 8 wks after 
aortic banding (AB 8 wks) in untreated control (first 3 lanes) and their 
corresponding hydrogen sulfide (H2S) treated groups (last 3 lanes).Densitometry 
analysis of the protein expression in arbitrary units was depicted in bar diagram. 
Each bar represents mean ± SE from n= 6 per group and *p <0.05 compared 
with untreated sham, #p<0.05 compared to their corresponding untreated 
controls. 
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Figure 50: Western blot analysis of matrix metalioproteinases-2 &-9 (MMP-2,-9) 
and tissue inhibitor of matrix metalioproteinase-3 (TIMP-3) in sham, 3 weeks 
after aortic banding (AB 3 wks) and 8 wks after aortic banding (AB 8 wks) in 
untreated control (first 3 lanes) and their corresponding hydrogen sulfide (H2S) 
treated groups (last 3 lanes). Densitometry analysis of protein expression in 
arbitrary units was depicted in bar diagram. Each bar represents mean ± SE from 
n=6 per group.*p <0.05 compared with untreated sham, #p<0.05 compared to 
their corresponding untreated controls. 
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Discussion 
Previously we have reported that during compensatory hypertrophy, there 
was increase in the expression of MMP-2, which promotes the production of 
VEGF. Subsequently, we have shown that in decompensatory phase, MMP-9 
expression supersedes MMP-2 expression and induces the production of anti 
angiogenic factors, endostatin and angiostatin. This causes the release of TIMP-
3, resulting in decreased angiogenesis and progression to heart failure. 
In the present study, we show that H2S promotes angiogenesis by 
inducing MMP-2 production and by inhibiting anti-angiogenic factors endostatin 
and angiostatin. H2S also decreases the level of MMP-9 and TIMP-3, thereby 
arresting the conversion from compensatory cardiac hypertrophy to heart failure 
(Figure 19). Our results showed that the treatment of pressure overload mice 
with H2S increases the production of angiogenic factors like VEGF. This 
promotes the increase in angiogenesis, and thereby, normalizes the capillary 
density and myocyte imbalance. Similarly, MMP-2 expression also increased in 
the H2S treated groups, especially in AS 8 weeks group, supporting the 
hypothesis that MMP-2 as an angiogenic promoter, induced VEGF production. 
Interestingly, we observed that MMP-9 expression decreased in the H2S treated 
groups along with the expression of anti angiogenic factors like angiostatin, 
endostatin and TIMP-3. Since we previously reported that MMP-9 promotes anti-
angiogenic factor production and TIMP-3 instigates apoptosis, these results 
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suggest the role of hydrogen sulfide in inhibiting both anti-angiogenic factor 
production and apoptosis by regulating the MMPfTlMP axis. 
Previous studies show that TIMP-3 has strong anti-angiogenic activity that 
can be seen in all stages of angiogenesis (57). MMP-9 is shown to be induced in 
heart failure and generates anti-angiogenic factors, endostatin and angiostatin 
(41, 47-48). Researchers report that the MMP-2 expression and activity is 
significantly elevated in VEGF treated hypertrophied hearts (42). This 
unequivocally suggests that MMP-9 is an anti-angiogenic and MMP-2 is a pro-
angiogenic factor. The treatment with H2S promotes angiogenesis and thereby, 
inhibits the transition from compensatory cardiac hypertrophy to heart failure. 
Functional data from echocardiography and pressure-volume study also showed 
improvement in left ventricular function after treating with H2S in comparison to 
untreated control groups. 
Clinically, it is well known that heart disease is the leading cause of 
mortality not only in the United States but also in rest of the world. Hypertension 
is one of the main risk factors leading to heart disease. Our research provides an 
insight into the transition mechanism from compensatory cardiac hypertrophy to 
heart failure. The beneficial effects of H2S in impeding the transition will help in 
clinical outcomes of heart failure. 
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Conclusions 
Based on our results, we conclude that H2S plays a role in a) ameliorating 
left ventricular dysfunction following pressure overload, b) minimizing 
accumulation of collagen deposition in the perivascular and intracardiac 
parenchymal tissue, c) altering expression of MMPs and TIMPs and thus 
regulating ECM remodeling, d) promoting angiogenesis by stimulating the 
production of VEGF, e) inhibiting anti-angiogenic factors like endostatin and 
angiostatin. 
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CHAPTER VI 
SUMMARY AND CONCLUSION 
Heart failure is the number one cause of mortality in both men and women 
and is a major public health problem around the world. Heart failure is defined as 
a pathophysiological state in which an abnormality of cardiac function is 
responsible for the failure of the heart to pump blood at a rate commensurate 
with the requirements of the metabolizing tissues. The most important risk factors 
leading to heart failure are hypertension, myocardial ischemia, myocardial 
infarction, valvular disease, and diabetes. 
During hypertension, the increase in pressure overload on the heart 
produces a compensatory hypertrophy which slowly progresses to 
decompensatory heart failure. The relationship between capillary density and the 
size of myofiber is important in heart failure, as the fiber diameter increases the 
number of capillaries per square mm decreases (15). The data suggest that as 
the myocyte to capillary ratio increases during compensatory hypertrophy, it 
eventually will progress to terminal heart failure. The discovery of the 
involvement of MMPs and their natural inhibitors TIMPs, in the cardiac 
remodeling revolutionized the field of cardiac failure research. Investigators 
demonstrate that the alterations in the normal MMPITIMP balance induce cardiac 
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matrix remodeling, which plays an important role in the pathogenesis of 
hypertension-induced heart failure. Disruption of coordinated cardiac 
hypertrophy and angiogenesis leads to heart failure, suggesting the role of 
angiogenesis in the pathogenesis of heart failure. Promoting angiogenesis in 
severely hypertrophied hearts protects them from ischemic injury. Although the 
role of hypertension in the pathogenesis of heart failure is well established, the 
treatment of hypertension induced heart failure is unclear. The relatively recent 
discovery of H2S, as an endogenous gaseous transmitter has prompted 
investigators to use H2S as a therapeutic agent. Studies report that H2S is cardio 
protective in hypertension, ischemialreperfusion injury, and infarction, but its 
potential role as a therapeutic agent during transition from compensatory cardiac 
hypertrophy to heart failure has not been elucidated. 
In the present study, we propose that cardiac matrix remodeling during 
pressure overload is induced by an increase in angiogenic factors during 
compensatory cardiac hypertrophy. Sustained pressure overload causes an 
increase in anti-angiogenic factors that leads to decompensatory heart failure. 
We also hypothesize that H2S treatment mitigates the transition from 
compensatory hypertrophy to decompensatory heart failure. 
In the first set of experiments, we found that the pressure overload due to 
aortic banding increases expression of pro-angiogenic MMP-2, which in turn 
induces production of VEGF during compensatory cardiac hypertrophy. 
Overtime, chronic pressure overload induces an increase in expression of MMP-
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9 and TIMP-3, which induce collagen deposition and release of anti-angiogenic 
factors like endostatin and angiostatin, contributing to a decrease in 
angiogenesis and thus leading to decompensatory heart failure. 
In the second set of experiments, we showed that H2S treatment promotes 
angiogenesis through increased expression of MMP-2 and VEGF. H2S also 
inhibits the production of anti-angiogenic factors by blocking MMP-9fTIMP-3 
expression thus mitigating the transition from compensatory cardiac hypertrophy 
to heart failure. Therefore, H2S therapy may become a useful therapeutic agent, 
if applied during the compensatory phase of the hypertensive heart failure. 
Additional studies are needed to explore further mechanistic details to 
understand the pathological mechanism of transition from compensatory 
hypertrophy to heart failure. 
FUTURE STUDIES 
To further elucidate the mechanisms of heart failure due to pressure 
overload, it would be interesting to use transgenic mice models of MMP-2-1-, 
TIMP-3-1- and MMP-9-1- mice and study the effects of aortic banding in these 
animals. Results from these studies will provide confirmatory evidence of the pro-
angiogenic role of MMP-2 and anti-angiogenic role of MMP-9fTIMP-3. Also 
studies that selectively inhibit angiostatin and endostatin formation may promote 
angiogenesis and may reverse the decompensatory phase of heart failure. 
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LIST OF ABBREVIATIONS 
Aortic banding (A B) 
American Heart Association (AHA) 
Protein kinase B (AKT) 
Adenosine tri phosphate (ATP) 
Carbon monoxide (CO) 
Coronary artery disease (CAD) 
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Cyclic guanosine mono phosphate (cGMP) 
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Endothelial cells (ECs) 
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Extracellular signal regulated kinase (ERK) 
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Fibroblast growth factor (FGF) 
Focal adhesion kinase (FAK) 
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Guanosine triphosphate (GTP) 
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Heam oxygenase (HO) 
Hypoxia- inducible factor (HIF) 
Hydrogen sulfide (H2S) 
Institute Animal Care and use Committee (IACUC) 
Integrin (av~3) 
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Matrix metalloproteinase (MMP) 
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